William Blair Issues Pessimistic Outlook for ResMed Earnings

ResMed Inc. (NYSE:RMD) – Research analysts at William Blair dropped their Q3 2025 earnings per share estimates for shares of ResMed in a report issued on Monday, February 3rd. William Blair analyst M. Andrew now forecasts that the medical equipment provider will earn $2.32 per share for the quarter, down from their previous estimate of $2.37. The consensus estimate for ResMed’s current full-year earnings is $9.41 per share. William Blair also issued estimates for ResMed’s FY2026 earnings at $10.23 EPS.

Other equities analysts have also issued research reports about the company. JPMorgan Chase & Co. lifted their price objective on ResMed from $270.00 to $286.00 and gave the company an “overweight” rating in a research note on Friday, January 31st. Stifel Nicolaus started coverage on shares of ResMed in a research report on Friday, December 13th. They set a “hold” rating and a $250.00 price target for the company. StockNews.com upgraded ResMed from a “hold” rating to a “buy” rating in a research note on Tuesday, October 15th. Piper Sandler raised their target price on ResMed from $252.00 to $260.00 and gave the company a “neutral” rating in a research report on Friday, January 31st. Finally, Robert W. Baird increased their price objective on ResMed from $280.00 to $283.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, ResMed presently has an average rating of “Moderate Buy” and a consensus price target of $244.73.

ResMed Stock Performance

Shares of ResMed stock opened at $242.19 on Thursday. The company has a 50 day moving average price of $239.82 and a 200 day moving average price of $237.15. The firm has a market capitalization of $35.55 billion, a P/E ratio of 28.59, a PEG ratio of 1.69 and a beta of 0.70. The company has a quick ratio of 2.29, a current ratio of 3.33 and a debt-to-equity ratio of 0.13. ResMed has a 52 week low of $170.56 and a 52 week high of $263.05.

ResMed (NYSE:RMD) last released its quarterly earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 EPS for the quarter, beating analysts’ consensus estimates of $2.29 by $0.14. ResMed had a return on equity of 26.17% and a net margin of 25.34%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of RMD. Geode Capital Management LLC increased its position in shares of ResMed by 10.9% in the third quarter. Geode Capital Management LLC now owns 3,858,814 shares of the medical equipment provider’s stock valued at $939,114,000 after buying an additional 380,383 shares in the last quarter. Los Angeles Capital Management LLC grew its stake in ResMed by 60.0% in the 4th quarter. Los Angeles Capital Management LLC now owns 668,908 shares of the medical equipment provider’s stock valued at $152,973,000 after acquiring an additional 250,746 shares during the last quarter. Caisse DE Depot ET Placement DU Quebec grew its position in shares of ResMed by 726.3% in the third quarter. Caisse DE Depot ET Placement DU Quebec now owns 283,801 shares of the medical equipment provider’s stock valued at $69,281,000 after purchasing an additional 249,454 shares during the last quarter. Proficio Capital Partners LLC purchased a new position in shares of ResMed during the 4th quarter worth approximately $50,364,000. Finally, Nordea Investment Management AB raised its position in shares of ResMed by 92.7% during the 4th quarter. Nordea Investment Management AB now owns 448,151 shares of the medical equipment provider’s stock worth $103,214,000 after purchasing an additional 215,561 shares during the last quarter. Institutional investors and hedge funds own 54.98% of the company’s stock.

Insider Buying and Selling at ResMed

In other news, Director Witte Jan De sold 796 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $248.81, for a total value of $198,052.76. Following the transaction, the director now owns 6,723 shares of the company’s stock, valued at approximately $1,672,749.63. The trade was a 10.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Peter C. Farrell sold 2,000 shares of the stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $242.11, for a total value of $484,220.00. Following the sale, the director now directly owns 77,218 shares of the company’s stock, valued at approximately $18,695,249.98. This represents a 2.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 11,094 shares of company stock valued at $2,704,941 in the last quarter. Corporate insiders own 0.71% of the company’s stock.

ResMed Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 13th will be given a $0.53 dividend. The ex-dividend date of this dividend is Thursday, February 13th. This represents a $2.12 annualized dividend and a yield of 0.88%. ResMed’s dividend payout ratio is presently 25.03%.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.